Atogepant
- Generic Name
- Atogepant
- Brand Names
- Qulipta, Aquipta
- Drug Type
- Small Molecule
- Chemical Formula
- C29H23F6N5O3
- CAS Number
- 1374248-81-3
- Unique Ingredient Identifier
- 7CRV8RR151
- Background
Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021. While its approval was predated by two other members of the same drug family, namely ubrogepant and rimegepant, th...
- Indication
Atogepant is indicated for the preventive treatment of migraine in adults by the FDA, EMA, and Health Canada.
- Associated Conditions
- Episodic Migraine, Migraine
- Associated Therapies
- -
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 3000
- Registration Number
- NCT06603558
- Locations
- 🇰🇷
Hallym University Dongtan Sacred Heart Hospital /ID# 273581, Hwaseong, Gyeonggido, Korea, Republic of
🇰🇷Yonsei University Health System Severance Hospital /ID# 272639, Seoul, Seoul Teugbyeolsi, Korea, Republic of
🇰🇷Seoul National University Hospital /ID# 271892, Seoul, Seoul Teugbyeolsi, Korea, Republic of
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1300
- Registration Number
- NCT06241313
- Locations
- 🇩🇪
Studienzentrum Nord-West /ID# 258024, Westerstede, Niedersachsen, Germany
🇩🇪Universitaetsklinikum Duesseldorf /ID# 258078, Düsseldorf, Nordrhein-Westfalen, Germany
🇩🇪AmBeNet GmbH /ID# 258075, Leipzig, Sachsen, Germany
Migraine Medication Effects on Urinary Symptoms
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 200
- Registration Number
- NCT06212661
- Locations
- 🇺🇸
Cleveland Clinic, Main Campus, Cleveland, Ohio, United States
Atogepant in Real Life in Italy (GIANT)
- Conditions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- IRCCS San Raffaele Roma
- Target Recruit Count
- 500
- Registration Number
- NCT06136442
Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05892757
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, LLC /ID# 255452, Springfield, Missouri, United States
🇺🇸Icon /Id# 257525, Salt Lake City, Utah, United States
🇺🇸Icon /Id# 257524, San Antonio, Texas, United States
Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
- Conditions
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 523
- Registration Number
- NCT05861427
- Locations
- 🇯🇵
Konan Medical Center /ID# 245557, Kobe-shi, Hyogo, Japan
🇯🇵Nishinomiya Municipal Central Hospital /ID# 246571, Nishinomiya-shi, Hyogo, Japan
🇯🇵Yamaguchi Clinic /ID# 246370, Nishinomiya-shi, Hyogo, Japan
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
- Conditions
- Interventions
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 545
- Registration Number
- NCT05748483
- Locations
- 🇨🇿
Praglandia /ID# 247511, Prague, Praha 5, Czechia
🇩🇪Universitaetsklinikum Carl Gustav Carus Dresden /ID# 246040, Dresden, Sachsen, Germany
🇧🇪Universitair Ziekenhuis Brussel /ID# 246959, Jette, Bruxelles-Capitale, Belgium
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
- Conditions
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 450
- Registration Number
- NCT05711394
- Locations
- 🇺🇸
Rehabilitation & Neurological Services /ID# 248517, Huntsville, Alabama, United States
🇺🇸Preferred Research Partners /ID# 249729, Little Rock, Arkansas, United States
🇺🇸Advanced Research Center /ID# 251381, Anaheim, California, United States
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 650
- Registration Number
- NCT05707949
- Locations
- 🇺🇸
My Preferred Research LLC /ID# 250931, Miami, Florida, United States
🇺🇸Patient Priority Clinical Sites, LLC /ID# 250922, Cincinnati, Ohio, United States
🇺🇸Access Clinical Trials, Inc. /ID# 250914, Nashville, Tennessee, United States
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 263
- Registration Number
- NCT05264129
- Locations
- 🇺🇸
Advanced Research Institute - Ridgeline /ID# 242662, Ogden, Utah, United States
🇺🇸Clinvest Research LLC /ID# 242597, Springfield, Missouri, United States
🇺🇸Aventiv Research Columbus /ID# 242462, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.